Evidence map›Paper›PMID 38766070›Full record

ArticlebioRxiv : the preprint server for biology2024

Clinicogenomic characterization of inflammatory breast cancer.

Nolan Priedigkeit, Beth Harrison, Robert Shue, Melissa Hughes, Yvonne Li, Gregory J Kirkner, Liam F Spurr, Marie Claire Remolano, Sarah Strauss, Janet Files and 19 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors.

Nolan PriedigkeitDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Beth HarrisonHarvard Medical School, Boston, MA, USA.
Robert ShueDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Melissa HughesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Yvonne LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Gregory J KirknerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Liam F SpurrDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Marie Claire RemolanoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sarah StraussDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Janet FilesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Anne-Marie FeeneyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Libby GrantDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ayesha Mohammed-AbreuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ana Garrido-CastroDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Romualdo Barroso SousaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Brittany BychkovskyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Faina NakhlisHarvard Medical School, Boston, MA, USA.
Jennifer R BellonHarvard Medical School, Boston, MA, USA.
Tari A KingHarvard Medical School, Boston, MA, USA.
Eric P WinerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Neal LindemanHarvard Medical School, Boston, MA, USA.
Bruce E JohnsonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Lynette ShollHarvard Medical School, Boston, MA, USA.
Deborah DillonHarvard Medical School, Boston, MA, USA.
Beth OvermoyerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sara M TolaneyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Andrew CherniackDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nancy U LinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Filipa LynceDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-6615-7076

Funding

Tissue and Pathology CoreP50CA168504 · NCI · DANA-FARBER CANCER INST · PI Nabihah Tayob · 2013 to 2026
$30.1M
NCI NIH HHS P50 CA168504
6 · The paper itself

Abstract

Background: Inflammatory breast cancer (IBC) is a rare and poorly characterized type of breast cancer with an aggressive clinical presentation. The biological mechanisms driving the IBC phenotype are relatively undefined-partially due to a lack of comprehensive, large-scale genomic studies and limited clinical cohorts. Patients and Methods: A retrospective analysis of 2457 patients with metastatic breast cancer who underwent targeted tumor-only DNA-sequencing was performed at Dana-Farber Cancer Institute. Clinicopathologic, single nucleotide variant (SNV), copy number variant (CNV) and tumor mutational burden (TMB) comparisons were made between clinically confirmed IBC cases within a dedicated IBC center versus non-IBC cases. Results: Clinicopathologic differences between IBC and non-IBC cases were consistent with prior reports-including IBC being associated with younger age at diagnosis, higher grade, and enrichment with hormone receptor (HR)-negative and HER2-positive tumors. The most frequent somatic alterations in IBC involved Conclusion: Taken together, this study provides a comprehensive, clinically informed landscape of somatic alterations in a large cohort of patients with IBC. Our data support higher frequency of

Indexed as

Breast cancercancer genomicsinflammatory breast cancermetastasisTP53tumor profiling

Identifiers

PMID38766070
PMCPMC11100693

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.